Company intelligence / Profile preview
HISHOH Biopharma
Chuo-ku, Tokyo, Japanhishoh.jp ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
HISHOH Biopharma develops next-generation allergen immunotherapies using proprietary immunostimulatory compounds. Their lead asset, HSO‑001—a potent TLR4 agonist licensed from Daiichi Sankyo—is designed to enhance the efficacy of existing allergen therapies and shorten treatment duration. The company aims for remission of severe allergic diseases such as allergic rhinitis, asthma related to rhinitis, and food allergies. They are also advancing antibody and nucleic acid drug candidates targeting various immune pathways. Clinical results are not yet published; programs appear preclinical or at an early clinical stage.
- Therapeutic areas
- PulmonologyImmunology
- Modalities
- Immunostimulants (e.g., TLR4 agonists)Antibody drugs (mAbs)Nucleic acid drugs
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
BioLite Japan K.K.Mitsubishi UFJ CapitalDBJ Capital (investors/shareholders)Daiichi Sankyo (licensor of key compound)
Beyond the preview
Go deeper on HISHOH Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HISHOH Biopharma.